AbbVie’s Qulipta outperforms topiramate in Phase 3 migraine prevention trial
ABBV•AbbVie said Qulipta outperformed topiramate in the Phase 3 TEMPLE trial, with fewer discontinuations due to adverse events and greater reductions in migraine days.
1. Trial results
AbbVie announced Oct. 29, 2026, that Phase 3 TEMPLE results showed Qulipta outperformed topiramate for adult migraine prevention. The trial also found greater improvements with Qulipta in headache-related disability, migraine-specific quality of life and cognitive functioning.
